slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
211,831-211,860 of 319,975
01
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
02
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
03
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
04
The slide uses a structured grid layout to present key value drivers.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
05
The slide uses a Gantt-style visualization to show drug development stages.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
06
The slide uses a four-column layout to structure the disease overview.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
07
Uses a geographic map and a nested circle diagram to illustrate the treatment gap.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
08
The slide uses a process-oriented flow diagram to explain the mechanism of action for a combination therapy.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
09
The slide highlights the mechanism of action targeting multiple HBV transcripts.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
10
The slide outlines study design for Part 1, 2, and 3 of a clinical trial for chronic hepatitis B (cHBV).Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
11
Data presented at Global Hepatitis Summit 2023. Includes specific cohort N values and standard error (SE) in parentheses.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
12
The slide displays six longitudinal line charts representing different patient cohorts, with specific callouts for clinical outcomes.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
13
Clinical trial data showing individual patient responses over time.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
14
Data presented at EASL 2022. Shows correlation between T-cell activation and HBsAg reduction.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
15
The slide uses a bulleted list to present key safety outcomes, including lack of serious adverse events and specific laboratory findings.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
16
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
17
The slide outlines a clinical trial timeline and key efficacy metrics for a chronic hepatitis B (cHBV) treatment.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
18
The slide outlines two parallel study arms with randomization at week 24.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
19
The slide details a specific licensing deal, including financial terms and partner background.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
20
The slide uses a three-column layout to highlight key value propositions.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
21
Includes a line chart for efficacy over time and two bar charts for pharmacokinetic concentrations in plasma vs liver.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
22
Includes IC50 value and IFN-y fold increase data.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
23
The slide uses a three-column layout to explain the scientific basis and product profile.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
24
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
25
Includes a schematic of the SARS-CoV-2 genome and protein structure, alongside specific drug development strategies.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
26
The slide uses a three-pillar framework to summarize the drug's value proposition.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
27
Includes financial metrics (cash balance, runway, burn) as context for the milestones.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
28
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
01
argenx SE | Investor Presentation Deck | 26 slidesargenx SE | Investor Presentation Deck | 26 slides · argenx
Conference presentation Investor relations Beat · Setup1 hit
02
argenx SE | Investor Presentation Deck | 26 slidesargenx SE | Investor Presentation Deck | 26 slides · argenx
Conference presentation Investor relations Beat · Setup1 hit